Study of Tyroserleutide for Injection in Hepatocellular Carcinoma (HCC) Patients
Status:
Unknown status
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blinded, placebo-controlled, multi-center Clinical Trial.
Patients with no tumor lesions one month after resection of hepatocellular carcinoma will be
randomized in a 1:1 ratio to 1 of the 2 treatment groups：6mg/d Tyroserleutide (injection), or
placebo.
The objective is to evaluate the effect of Injectable Tyroserleutide on the recurrence-free
survival,overall survival,quality of life,and the safety and tolerability of subjects after
the resection of hepatocellular carcinoma